Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast

Accepts healthy volunteers
erbb2
pertuzumab
HER2
trastuzumab
  • 0 views
  • 08 Apr, 2022
  • 1 location
Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for

erbb2
estradiol
epidermal growth factor receptor
HER2
tamoxifen
  • 0 views
  • 11 Jul, 2021
  • 5 locations
Phase I Study to Evaluate SCR-6852 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

estrogen receptor
erbb2
epidermal growth factor receptor
HER2
palbociclib
  • 0 views
  • 08 Jun, 2022
  • 1 location
Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer

this study is to evaluate the efficacy of dose-dense nab-paclitaxel compared with dose-dense docetaxel followed by anthracycline and cyclophosphamide in the treatment of HR positive and HER-2 negative

erbb2
cyclophosphamide
mammogram
paclitaxel
anthracyclines
  • 1 views
  • 20 Feb, 2022
  • 1 location
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This is a prospective, single-arm, open-label phase II study, designed to evaluate the efficacy and safety of pyrotinib

  • 0 views
  • 03 Feb, 2021
  • 1 location
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

, HER-2 and HER-4 receptors. More general inhibition of ErbB family with pyrotinib could provide additional benefit. This study is designed to evaluate the efficacy and safety of pyrotinib in

erbb2
HER2
advanced breast cancer
trastuzumab
endocrine therapy
  • 4 views
  • 03 May, 2022
  • 1 location
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

limit the tumor size, and the tumor size of some patients was greater than 5 cm; the hormone status of the patients was not limited, about 1/3 of the patients were ER negative, and the HER-2 status of

erbb2
epidermal growth factor receptor
paclitaxel
HER2
advanced breast cancer
  • 0 views
  • 06 May, 2022
  • 1 location
Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer

positive HER-2, additional Herceptin could improve the response further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin should be evaluated and the role in predicting

core needle biopsy
erbb2
cancer
trastuzumab
MRI
  • 7 views
  • 21 Jan, 2021
  • 2 locations
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is a randomized, open-label, multi-center, parallel design study of the combination of

  • 0 views
  • 10 May, 2022
  • 1 location
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

progesterone receptor positive, HER-2 negative breast cancer. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy rays to

ductal carcinoma
erbb2
cancer
tumor cells
HER2
  • 0 views
  • 13 Jun, 2022
  • 5 locations